Physics-aware imaging AI for quantitative MASLD biomarker mapping: a systematic review of deep learning and radiomics across ultrasound, CT, and MRI
Abdominal Radiology · 26.11.2025 · 51 (6) · 2919-2931
DOI: 10.1007/s00261-025-05317-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Abdominal Radiology, online erschienen am 26.11.2025. Verfasst von Houshyar Maghsoudi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Baqiyatallah University of Medical Sciences, Tehran, Iran, Islamic Republic of. Hauptthemen laut MEDLINE: Deep Learning, Fatty Liver, Artificial Intelligence. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This systematic review critically appraises the current landscape of physics-aware artificial intelligence (AI) in medical imaging for quantitative biomarker mapping in Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, MASH. It focuses on deep learning and radiomics applications across ultrasound, CT, and MRI. METHODS: A PRISMA 2020-guided systematic review was conducted, searching PubMed, Scopus, and Web of Science from 2015 to 2025. Studies applying AI to imaging for automated segmentation, quantitative steatosis/iron/fibrosis mapping, or staging in MASLD/MASH were included. Data on technical approaches, physics-aware design, reference standards, performance, and deployment readiness were extracted and synthesized narratively. RESULTS: Of 842 identified records, 33 studies were included. MRI leads in biophysically-grounded fat/iron quantification (PDFF, R2*) using confounder-corrected sequences and automated whole-liver segmentation. CT excels in scalable, opportunistic steatosis assessment via fully automated volumetric attenuation and dual-energy virtual non-contrast, though performance is phase-dependent. Ultrasound bifurcates into physics-informed quantitative ultrasound (attenuation/backscatter) correlating with MRI-PDFF and B-mode deep learning for steatosis grading, with emerging domain-adaptation techniques. Evidence strength and external validation are most robust for CT and MRI automation, while ultrasound methods are advancing in generalizability. Key gaps include standardized longitudinal pipelines, multi-vendor harmonization, and MASLD-specific fibrosis validation. CONCLUSION: Imaging AI for MASLD/MASH is converging on physics-consistent, automated quantitative mapping. Deployment readiness is highest for CT attenuation and MRI PDFF/R2* pipelines. Future work requires prospective, multicenter validation integrating physics-aware design, rigorous confounder control, and standardized reporting to enable reliable clinical integration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baqiyatallah University of Medical Sciences, Tehran, Iran, Islamic Republic of.
- Baqiyatallah University of Medical Sciences, Tehran, Iran, Islamic Republic of. dr.khonche@yahoo.com.
- Aja University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Zitieren
APA
Maghsoudi, H., Khonche, A., Gereami, R., & Gharebakhshi, F. (2025). Physics-aware imaging AI for quantitative MASLD biomarker mapping: a systematic review of deep learning and radiomics across ultrasound, CT, and MRI. Abdominal Radiology, 51(6), 2919-2931. https://doi.org/10.1007/s00261-025-05317-9
Vancouver
Maghsoudi H, Khonche A, Gereami R, Gharebakhshi F. Physics-aware imaging AI for quantitative MASLD biomarker mapping: a systematic review of deep learning and radiomics across ultrasound, CT, and MRI. Abdominal Radiology. 2025;51(6):2919-2931. doi:10.1007/s00261-025-05317-9
BibTeX
@article{Maghsoudi2025,
author = {Maghsoudi, Houshyar and Khonche, Ahmad and Gereami, Reza and Gharebakhshi, Farshad},
title = {Physics-aware imaging AI for quantitative MASLD biomarker mapping: a systematic review of deep learning and radiomics across ultrasound, CT, and MRI},
journal = {Abdominal Radiology},
year = {2025},
volume = {51},
number = {6},
pages = {2919--2931},
doi = {10.1007/s00261-025-05317-9}
}
EUVIMED